CurrentUnitedHealthcarePolicy CS151KY.07

Carrier Testing Genetic Diseases Ky Cs

UnitedHealthcare medical policy (Kentucky only) defining medical necessity for reproductive carrier screening panels (by panel size and indications), recommended counseling, definitions, supporting evidence summary, and applicable procedure codes. This part (1 of 2) contains coverage rationale, definitions, descriptions of services, guidance for Ashkenazi Jewish and pan-ethnic screening, literature review and applicable CPT/HCPCS codes listed for reference.

Policy Summary

PayerUnitedHealthcare

PolicyCarrier Testing Genetic Diseases Ky Cs

Policy CodePolicy CS151KY.07

Change TypeRevised definitions & supporting sections

Effective DateJul 1, 2025

Next Review Date

Key ActionWhen ordering a reproductive carrier screening panel of up to 15 genes, document that the individual or reproductive partner meets Ashkenazi Jewish ancestry or a biological first- or second-degree relative is affected; provide or arrange pre-test genetic counseling and document it.

SourceLink

POLICY UPDATE CHANGES

Updated definition of 'Gene Panel' and supporting sections (Clinical Evidence, FDA, References); previous policy version CS151KY.06 archived.

2Recommended specific genes (CFTR and SMN1)

<=15Genes allowed with criteria

>=16Panels considered not medically necessary (gene count)

1/66

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Individuals in US with hemoglobinopathy trait

110Genes in example ECS study

346,790Individuals screened in Haque et al. model

Coverage Summary

UnitedHealthcare Kentucky policy CS151KY.07 (effective 2025-07-01) defines medical necessity for reproductive carrier screening panels by panel size and specific indications. The policy takes a mixed coverage stance: panels of up to 6 genes are proven and medically necessary for general reproductive carrier screening, and panels of up to 15 genes are proven and medically necessary when the individual or reproductive partner has Ashkenazi Jewish ancestry (at least one parent or grandparent) or when a biological first‑ or second‑degree relative is affected by a condition on the panel. Panels of 16 or more genes are considered not medically necessary.

Quick policy facts and panel thresholds

Panel size threshold - proven medically necessaryUp to 6 genes general; Up to 15 genes when individual or reproductive partner has Ashkenazi Jewish ancestry OR a biological first- or second-degree relative affected

Panel size threshold - not medically necessaryPanels comprised of 16 or more genes are unproven and not medically necessary

policy_numberCS151KY.07

subjectCarrier Testing Panels for Genetic Diseases (Kentucky)

statusCURRENT

effective_dateJuly 1, 2025

Medical-Necessity Criteria

Pre-test Counseling

Counseling recommendation

Pre-test genetic counseling is strongly recommended to inform persons being tested about the advantages and limitations of the test as applied to a unique person.

Provider Actions & Documentation Requirements

Documentation Required

Document indication for larger panels (up to 15 genes)

When ordering a reproductive carrier screening panel of up to 15 genes, document the specific indication for the larger panel. Record either that the individual (or their reproductive partner) has Ashkenazi Jewish ancestry (at least one parent or grandparent of Ashkenazi Jewish descent) or that a biological first- or second-degree relative is affected by one or more of the conditions evaluated by the panel.

Document Ashkenazi Jewish ancestry: at least one parent or grandparent of AJ descent.
Or document a biological First- or Second-Degree Relative affected by a condition evaluated by the panel.

Documentation Required

Recommend pre-test genetic counseling

Provide or arrange pre-test genetic counseling and document that counseling occurred or that it was recommended prior to testing.

Document that pre-test genetic counseling was provided or that referral/arrangement for counseling was made.

Coding (Reference Codes)

Referenced Procedure Codes (provided for reference only)mixed

0400U	Obstetrics (expanded carrier screening), 145 genes by next generation sequencing, fragment analysis and multiplex ligation dependent probe amplification, DNA, reported as carrier positive or negative.
81412	Ashkenazi Jewish associated disorders genomic sequence analysis panel, must include sequencing of at least 9 genes (e.g., ASPA, BLM, CFTR, FANCC, GBA, HEXA, IKBKAP, MCOLN1, SMPD1).
81443	Genomic sequence analysis panel, must include sequencing of at least 15 genes (examples listed include ACADM, ARSA, ASPA, ATP7B, BCKDHA, BCKDHB, BLM, CFTR, etc.).
81479	Unlisted molecular pathology procedure.

Background and Definitions

Carrier screening identifies asymptomatic individuals who may carry variants for autosomal recessive or X-linked conditions that can affect reproductive decisions. Next‑generation sequencing (NGS) enables multi-gene panels to screen many genes simultaneously. Professional guidance supports screening for cystic fibrosis (CF), spinal muscular atrophy (SMA), and hemoglobinopathies in all individuals who are pregnant or considering pregnancy, and recommends consideration of tiered or frequency-based approaches to panel composition (ACOG and ACMG).

Glossary:

Carrier Screening: Genetic testing of an asymptomatic individual to determine whether they may have a variant that could be passed to biological children.

First‑Degree Relative: Parents, siblings, and children.

Second‑Degree Relative: Half siblings, aunts, uncles, grandparents, grandchildren, and nieces/nephews.

Gene Panel: A test that looks for genetic changes/variants in more than one gene in the same test (definition updated in this policy).

Expanded Carrier Screening (ECS): Panels that screen multiple autosomal recessive and X‑linked conditions across populations rather than ethnicity‑based targeted screening.

Tiered carrier screening (ACMG): A tiered approach (Tier 1 through Tier 4) based on carrier frequency to guide panel composition (e.g., Tier 3 includes conditions with carrier frequency ≥1/200 and X‑linked conditions).

Pan‑ethnic screening: Offering screening irrespective of self‑reported ethnicity to avoid misses from inaccurate self‑reporting or admixture.

Clinical Evidence Summary

Supporting clinical evidence is summarized below and includes systematic reviews, large cohort studies, and comparative analyses that evaluate detection rates, impact on reproductive decision‑making, and differences between expanded/pan‑ethnic and ethnicity‑based panels.

Study type / citation	Key findings
Systematic review / meta-analysis (Wang et al. 2023a)	RCS detected 1–24 high-risk couples per 1000 screened; pooled prenatal diagnosis (PND) rate 0.644, termination rate 0.714, and IVF with PGT rate 0.631; more conditions screened associated with reduced PND/termination; authors call for additional study and highlight importance of genetic counseling.
Large cohort (Johansen Taber et al. 2022)	460,608 individuals screened; 37 conditions met conservative thresholds and 74 met liberal thresholds; panels of 37 or 74 conditions capture major guideline-recommended conditions and detect 63%–81.4% of carriers and 84.6%–96.6% of at-risk couples depending on threshold.
Comparative studies (Peyser et al. 2019; Rosenblum et al. 2020)	ECS identifies substantially more carriers than ethnicity-based or smaller panels (e.g., Peyser: 29.4% carriers by ECS vs 15.6% ACOG-based vs 8.5% ethnicity-based; Rosenblum: pan-ethnic panel found higher carrier detection vs AJ-specific panel and would have missed carriers if limited to AJ panel).
Study sample size (Haque et al. 2016)	Modeled fetal risk based on 346,790 individuals screened (ECS panels up to 110 genes); targeted genotyping and NGS platforms identified thousands of carriers across platforms (e.g., 47,590 carriers by targeted genotyping; 11,088 carriers by NGS subset).
Positive finding rate (NextGen genomics-based screening study)	78% of participants had at least one finding in the genomics-based screening arm (NextGen study reported 78% with ≥1 finding).
Genetic counselor prep time (NextGen study)	Median 64 minutes required for a genetic counselor to prepare for a follow-up visit for positive results.

Revision History

2025-07-01policy_updateLatest

Summary of Changes dated 07/01/2025: Updated definition of 'Gene Panel' and updated supporting sections (Clinical Evidence, FDA, References); previous policy version CS151KY.06 archived.

2025-07-01policy_effectiveLatest

Policy number CS151KY.07 effective July 1, 2025 — UnitedHealthcare Carrier Testing Panels for Genetic Diseases (Kentucky only) defining coverage criteria by panel size and indications.

Policy Summary

PayerUnitedHealthcare

PolicyCarrier Testing Genetic Diseases Ky Cs

Policy CodePolicy CS151KY.07

Change TypeRevised definitions & supporting sections

Effective DateJul 1, 2025

Next Review Date

SourceLink

On This Page

Documentation Required

Offer hemoglobinopathy testing to all planning pregnancy or at first prenatal visit

Offer hemoglobinopathy testing (for example, hemoglobin electrophoresis or molecular genetic testing) to all individuals planning a pregnancy or at the first prenatal visit if no prior testing has been performed, and document that testing was offered and performed or that prior testing existed.

Document whether hemoglobinopathy testing was performed, or that the testing was offered and declined.
If prior testing exists, document prior results.

Documentation Required

Offer CF, SMA carrier screening to all pregnant or preconception individuals

Offer carrier screening for cystic fibrosis (CF) and spinal muscular atrophy (SMA), along with complete blood count and screening for thalassemias/hemoglobinopathies, to all individuals who are pregnant or considering pregnancy, and document that these offers and any testing or counseling were made.

Document that CF and SMA carrier screening were offered.
Document that CBC and thalassemia/hemoglobinopathy screening were offered or performed.

Documentation Required

Offer Tier 3 ACMG carrier screening

Offer Tier 3 ACMG carrier screening (conditions with carrier frequency ≥ 1/200, including Tier 2 and X-linked conditions) to all pregnant patients and those planning a pregnancy, and document the offer and whether testing was accepted or declined.

Document that Tier 3 (≥ 1/200 carrier frequency, includes Tier 2 and X-linked conditions) screening was offered to the patient.
If testing performed, document which tier/panel was used and test results or that testing was declined.

Documentation Required

ECS offering per NSGC guideline

Offer expanded carrier screening (ECS) in accordance with the NSGC guideline: offer to all individuals considering reproduction, pregnant individuals, their partners, and others who might biologically contribute to the pregnancy. Use shared decision-making and provide genetic counseling; document the counseling discussion, the shared decision-making process, and whether ECS was accepted or declined.

Document that ECS was offered and that shared decision-making occurred.
Document that genetic counseling was provided or a referral/arrangement was made.
Note patient values and preferences that informed the decision to accept or decline ECS.

Optional quick facts from policy stats

Recommended specific genes (CFTR and SMN1)2

Genes allowed with criteria<=15 (when Ashkenazi Jewish ancestry OR first/second-degree relative affected); up to 6 genes otherwise

Panels considered not medically necessary (gene count)>=16

Individuals in US with hemoglobinopathy trait1 in 66

Coverage criteria specify reproductive carrier screening panels of up to 6 genes are proven and medically necessary; panels up to 15 genes are proven and medically necessary when Ashkenazi Jewish ancestry or a biological first- or second-degree relative is affected; panels of 16 or more genes are unproven and not medically necessary.